Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.

Εμφάνιση άλλων εκδόσεων (1)

OBJECTIVE: To determine the relation between concentrations of prostate specific antigen at age 60 and subsequent diagnosis of clinically relevant prostate cancer in an unscreened population to evaluate whether screening for prostate cancer and chemoprevention could be stratified by risk. DESIGN: Ca...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Vickers, A, Cronin, A, Björk, T, Manjer, J, Nilsson, P, Dahlin, A, Bjartell, A, Scardino, P, Ulmert, D, Lilja, H
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	2010

Παρόμοια τεκμήρια

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: Case-control study
ανά: Vickers, A, κ.ά.
Έκδοση: (2010)

Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.
ανά: Lilja, H, κ.ά.
Έκδοση: (2011)

Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men.
ανά: Klein, R, κ.ά.
Έκδοση: (2012)

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
ανά: Lilja, H, κ.ά.
Έκδοση: (2008)

Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study.
ανά: Ulmert, D, κ.ά.
Έκδοση: (2008)

A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening.
ανά: Vickers, A, κ.ά.
Έκδοση: (2011)

Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening.
ανά: Savage, C, κ.ά.
Έκδοση: (2010)

Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring (Corrigendum) (Nature Reviews Cancer (2008) 8, (268-278))
ανά: Lilja, H, κ.ά.
Έκδοση: (2008)

Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study
ανά: Berglund Göran, κ.ά.
Έκδοση: (2008-02-01)

Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.
ανά: Ulmert, D, κ.ά.
Έκδοση: (2008)

Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone.
ανά: Evans-Axelsson, S, κ.ά.
Έκδοση: (2012)

Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively.
ανά: O'Brien, M, κ.ά.
Έκδοση: (2011)

The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy.
ανά: Vickers, A, κ.ά.
Έκδοση: (2007)

Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
ανά: Lilja, H, κ.ά.
Έκδοση: (2007)

Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy.
ανά: Vickers, A, κ.ά.
Έκδοση: (2010)

Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.
ανά: Vickers, A, κ.ά.
Έκδοση: (2010)

Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer.
ανά: Christensson, A, κ.ά.
Έκδοση: (2011)

Five genetic variants associated with prostate cancer.
ανά: Vickers, A, κ.ά.
Έκδοση: (2008)

Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort.
ανά: Vickers, A, κ.ά.
Έκδοση: (2009)

Prostate kallikrein markers in diagnosis, risk stratification and prognosis.
ανά: Ulmert, D, κ.ά.
Έκδοση: (2009)

Time-resolved fluorescence imaging for specific and quantitative immunodetection of human kallikrein 2 and prostate-specific antigen in prostatic tissue sections.
ανά: Siivola, P, κ.ά.
Έκδοση: (2000)

Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.
ανά: Cao, Y, κ.ά.
Έκδοση: (2002)

Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer.
ανά: Steuber, T, κ.ά.
Έκδοση: (2007)

An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.
ανά: Vickers, A, κ.ά.
Έκδοση: (2011)

Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C.
ανά: Ulmert, D, κ.ά.
Έκδοση: (2006)

Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy.
ανά: Wenske, S, κ.ά.
Έκδοση: (2009)

Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen.
ανά: Ulmert, D, κ.ά.
Έκδοση: (2012)

Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer.
ανά: Vickers, A, κ.ά.
Έκδοση: (2009)

Addition of Prostate Volume and Prostate-specific Antigen Density to Memorial Sloan Kettering Cancer Center Prostate Cancer Nomograms
ανά: Michael Tzeng, κ.ά.
Έκδοση: (2021-08-01)

Biology of prostate-specific antigen
ανά: Lilja, H
Έκδοση: (2003)

Biology of prostate-specific antigen.
ανά: Lilja, H
Έκδοση: (2003)

Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.
ανά: O'Brien, M, κ.ά.
Έκδοση: (2009)

The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group.
ανά: Vickers, A, κ.ά.
Έκδοση: (2010)

A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.
ανά: Vickers, A, κ.ά.
Έκδοση: (2010)

Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer.
ανά: Klein, R, κ.ά.
Έκδοση: (2010)

Expression of prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues.
ανά: Olsson, A, κ.ά.
Έκδοση: (2005)

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden.
ανά: Vickers, A, κ.ά.
Έκδοση: (2008)

The continuing role of prostate-specific antigen as a marker for localized prostate cancer: 'do not throw the baby out with the bath water'.
ανά: Challacombe, B, κ.ά.
Έκδοση: (2009)

Screening for prostate cancer: an update.
ανά: Shariat, S, κ.ά.
Έκδοση: (2008)

Tumor markers in prostate cancer I: blood-based markers.
ανά: Shariat, S, κ.ά.
Έκδοση: (2011)